非小细胞肺癌患者表皮生长因子受体基因突变的异质性

发布时间：2019-03-30 17:26

【摘要】：目的:探讨非小细胞肺癌(NSCLC)患者表皮生长因子受体(EGFR)基因突变的异质性。方法:收集本院165例NSCLC患者有成对肺癌石蜡包埋组织标本,采用ARMS-PCR技术进行EGFR突变分析,并统计EGFR突变异质性情况。结果:165例成对的NSCLC标本中,女性患者的EGFR基因突变异质性率显著高于男性,差异有统计学意义(P0.05);年龄、吸烟情况和异质性组别的异质性率均无差异(P0.05);病例的总异质性率为20.0%(33/165),多发肺部结节患者的肿瘤异质性发生率最高(26.8%,19/71);EGFR突变异质性病例以腺癌居多,69.7%的病例出现一个部位样本为EGFR突变阳性,另一部位为EGFR突变野生型的现象。结论:NSCLC患者中存在EGFR基因突变异质性,多发性肺结节患者的异质性比例明显较高。
[Abstract]:Objective: to investigate the heterogeneity of epidermal growth factor receptor (EGFR) gene mutation in patients with non-small cell lung cancer (NSCLC). Methods: a total of 165 NSCLC patients were collected from paraffin-embedded tissues of lung cancer. EGFR mutations were analyzed by ARMS-PCR and the heterogeneity of EGFR mutations was analyzed. Results: the heterozygosity rate of EGFR gene mutation in female patients was significantly higher than that in male patients (P0.05), and there was no significant difference in age, smoking and heterozygosity between the two groups (P0.05). Results: there was no significant difference in EGFR gene mutation heterozygosity rate between female and male NSCLC patients (P0.05). The total heteroplasmy rate was 20.0% (33 / 165), and the incidence of tumor heterogeneity was the highest in patients with multiple pulmonary nodules (26.8%, 19 / 71). Adenocarcinoma was the most heterogeneous case of EGFR mutation. 69.7% of the cases showed positive EGFR mutation in one site and wild-type EGFR mutation in the other. Conclusion: there is heterogeneity of EGFR gene mutation in patients with NSCLC, and the percentage of heterogeneity in patients with multiple pulmonary nodules is significantly higher than that in patients with multiple pulmonary nodules.
【作者单位】：广州医科大学附属肿瘤医院检验科;广州医科大学附属肿瘤医院肿瘤研究所;广州医科大学附属肿瘤医院病理科;广州医科大学附属肿瘤医院胸外科;
【基金】：广东省科技计划项目(编号:2014A020212338)
【分类号】：R734.2

【相似文献】